Related Experiment Video
Updated: Sep 17, 2025

Development of an In Vitro Ocular Platform to Test Contact Lenses
Published on: April 6, 2016
Post-market Surveillance Analysis of Refractive Data in Users of Delivery Tyro®, a Tyrosine-Releasing Contact Lens
Diego Ponzin1, Adriano Fasolo1, Giancarlo Montani2
1The Veneto Eye Bank Foundation, Venice, Italy.
Introduction:
Myopia is a growing public health concern, particularly among young individuals. Several pharmacological and optical interventions exist to slow its progression, yet each has limitations. In January 2021, Safilens introduced the Delivery Tyro® daily disposable contact lens, which releases hyaluronic acid, tamarind seed polysaccharide, and tyrosine, a dopamine precursor with antioxidative and cytoprotective properties.
Methods:
This study analyzed post-market surveillance data collected by 55 optometrists from 241 myopic subjects (mean age, 14.73 years; mean initial spherical equivalent (SE) refraction, - 2.72 diopters [D]) over a 12-month period of bilateral Delivery Tyro® lens use. The purpose of the analysis was to compare the observed myopia progression in Delivery Tyro® users with expected rates based on control SE refraction data derived from meta-analyses of similar age and ethnic cohorts.
Results:
Delivery Tyro® users experienced slower rates of myopia progression than expected. After 12 months of lens wear, the average change in SE was a - 0.04 D compared with the expected change of - 0.28 D from the reference control group (P < 0.001). Furthermore, 94% of eyes exhibited no significant change in SE (defined as a change of - 0.25 D or less).
Conclusions:
These findings support the hypothesis that Delivery Tyro® may reduce myopia progression, likely attributable to the release of tyrosine during lens wear, either due to its antioxidative properties or its role as a precursor of dopamine, a key neurotransmitter in the retina involved in visual signaling, and refractive development. Given the convenience of daily disposable lenses, Delivery Tyro® may offer a practical solution for myopia management, particularly for young patients at elevated risk of rapid myopia progression due to genetic and environmental factors. Further confirmation of the efficacy of Delivery Tyro® through controlled, randomized clinical trials is warranted.
More Related Videos
05:46Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
Published on: September 20, 2024
06:55Scanning Light Scattering Profiler SLPS Based Methodology to Quantitatively Evaluate Forward and Backward Light Scattering from Intraocular Lenses
Published on: June 6, 2017